Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus. Issue 7 (23rd July 2019)

• Record Type: Journal Article
• Authors: Yan, Yang; Xu, Hu; Wang, Jiandong; Wu, Xin; Wen, Wei; Liang, Yan; Wang, Lingdi; Liu, Fengyuan; Du, Xiaohui
• Is Part Of: Bioscience reports. Volume 39:Issue 7(2019)
• Publication Date: 2019-07-23
• Subjects: breast cancers -- E2F-1 -- IL-15 -- Oncolytic adenovirus; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20190384
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : The wide application of oncolytic adenovirus presents a novel therapeutic strategy for breast cancer gene therapy. Application of adenovirus alone achieves little curative effects on breast cancer. In addition, it is worth exploring the synergistic anti-tumor effect by inserting immunomodulatory factor in oncolytic adenovirus genome. By taking the advantage of the highly proliferative property of breast cancer, a novel recombinant adenovirus which could selectively kill tumor cells is established under an E2F-1 promoter. Also by carrying human Interleukin-15 (IL-15) gene, the oncolytic adenovirus exhibits an immunomodulatory effect. The present study proved that the novel oncolytic virus (SG400-E2F/IL-15) exhibits an enhanced anti-tumor activity both in vitro and in vivo, representing an experimental basis for breast cancer "virus-gene" therapy.